Table 5. Treatments and prognoses in adult SARI patients in a surveillance hospital in Jinshan, Shanghai, April 2017 to March 2018.
| Characteristics | SARI patients | P value* | ||
|---|---|---|---|---|
| All (%) [n = 397] | With confirmed pathogens (%) [n = 250] | Without confirmed pathogens (%) [n = 147] | ||
| Clinical course (median, days) | ||||
| From illness onset to admission | 3 | 3 | 3 | 0.567 |
| Length of hospitalization | 10 | 10 | 10 | 0.545 |
| Antibiotics prior to hospitalization | 241(61.0) | 151(60.9) | 90(61.2 | 0.723 |
| Antibiotics during hospitalization | 393(99.0) | 246(98.4) | 147(100) | 0.301 |
| Antivirals | 11(2.8) | 7(2.8) | 4(2.7) | 1.000 |
| Glucocorticoids | 112(28.2) | 72(27.2) | 40(28.8) | 0.734 |
| Oxygen therapy | 196(49.4) | 124(49.6) | 72(49.0) | 0.918 |
| Complications | 61(15.4) | 37(14.8) | 24(16.3) | 0.684 |
| Death | 3(0.8) | 2(0.8) | 1(0.7) | 1.000 |
*P values denote comparisons between SARI patients with confirmed pathogens and SARI patients without confirmed pathogens.